Ann: Quarterly Activity Report & Appendix 4C, page-56

Great post, @Jambon1

Measuring glucose utilization would be very beneficial, if possible. As I'm sure you are aware, T2D patients that have not reached B cell exhaustion may still produce insulin, but insulin sensitivity is compromised leading to increased blood glucose. If patients are able to produce greater insulin which decreased blood glucose, then I think you have a clinically relevant outcome worth pursuing. I would be very interested to know if m6A modifications were involved in insulin sensitivity (I strongly assume they are) and more specifically whether FTO overexpression is in part implicated in declining insulin sensitivity. If that is the case, then an FTO inhibitor could play two roles in an organism: A) improve insulin secretion from pancreas; and B) improve glucose utlization by muscle and fat cells. Also, it would be interesting to know if patients whose B cells have exhausted are able to produce insulin again.

For those asking where I have been, thank you for thinking about me. Just taking some time out to enjoy the Perth weather and work on two handed dunks.